Updated on 14 February 2013
Sigma-Aldrich's innovative biological products business Sigma Life Science collaborates with University of Tokyo researchers to develop Lentiviral microRNA Inhibitors
Singapore: Sigma-Aldrich's innovative biological products and services business Sigma Life Science signed an exclusive collaboration with Dr Hideo Iba and Dr Takeshi Haraguchi at the University of Tokyo to release Mission synthetic and Lentiviral microRNA Inhibitors. These are based upon the Tough Decoy (TuD) design for the long-term suppression of any miRNA endogenous to humans or mice.
Custom designs for other species are available upon request. Each microRNA inhibitor is designed using a proprietary algorithm that evaluates all possible sequences for the design predicted to best maintain the TuD structure, providing maximal miRNA recognition and binding.
Naturally-occurring miRNAs inhibit translation of a large percentage of mRNAs encoding human proteins and play pivotal roles in oncogenesis, development, cell differentiation, and immune responses. Iba and Haraguchi invented TuD RNAs1,2 as a more potent tool to suppress specific miRNAs and thus investigate their biological functions.
In contrast to current approaches that use single-stranded RNAs, such as sponge decoys and locked nucleic acids, TuD RNAs are double-stranded. This, along with a stem-loop stabilized secondary structure, resists cellular nuclease degradation and facilitates sustained miRNA inhibition for longer than one month. In addition, both strands of a TuD RNA contain an miRNA binding site for more efficient sequestration of target miRNAs at lower, nanomolar concentrations.
"Drs Iba and Haraguchi's Tough Decoy RNAs are an elegant and more practical tool for exploring the impact of microRNA gene regulation on human disease. Sigma Life Science's mission is to support this field's rapid development by making keystone technologies like this broadly accessible," says Dr Supriya Shivakumar, director of emerging technologies at Sigma Life Science.